Time to coronary angiography and revascularization in 575,247 patients with STEMI from 2012 to 2023: a retrospective

Paulina E Stürzebecher1, Ulrich Laufs1, Philip Baum2

  • 1Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Leipzig, 04103, Germany.

PubMed

Insights

Rapid primary percutaneous coronary intervention (PPCI) for ST-elevation myocardial infarction (STEMI) improved over time, but in-hospital mortality rose. Addressing delays outside regular hours and focusing on high-risk groups can further reduce STEMI mortality.

Area of Science:

  • Cardiology
  • Public Health
  • Health Services Research

Background:

  • ST-elevation myocardial infarction (STEMI) requires rapid treatment with primary percutaneous coronary intervention (PPCI) to reduce mortality.
  • Analysis of time intervals, risk factors for delays, and in-hospital mortality in STEMI patients receiving PPCI between 2012 and 2023.

Purpose of the Study:

  • To analyze trends in PPCI time intervals for STEMI patients in Germany.
  • To identify risk factors associated with delays in PPCI.
  • To examine in-hospital mortality rates and their correlation with treatment timeliness and patient demographics.

Main Methods:

  • Retrospective population-based analysis of hospital billing data for adult STEMI patients undergoing PPCI in Germany.
  • Estimation of transport time to hospital (TTH) using geographic routing.
  • Calculation of in-hospital time to angiography (IHTA) using PPCI time coding.

Main Results:

  • Over 575,000 patients were analyzed; in-hospital delay (IHTA) decreased significantly from 2012 to 2023, with improved overall treatment times (TTH + IHTA).
  • Despite improved timeliness, in-hospital mortality increased, paralleling rises in patient age and comorbidity.
  • Risk factors for delays included older age, female sex, comorbidities, out-of-hours presentation, and low-volume hospitals. Mortality risks were higher for women, older patients, those with comorbidities, and weekend/out-of-hours admissions.

Conclusions:

  • While in-hospital delays in PPCI for STEMI have decreased, overall mortality has risen, necessitating further improvements.
  • Targeting care outside regular hours and focusing on vulnerable populations (women, elderly, those with comorbidities) are crucial for reducing STEMI mortality.
Abstract

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
218
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
220
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
215
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
828
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
590
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
238